I will be participating in the community roundtable on drug shortages and the supply chain at 11 AM, and attending the session on environmental considerations across the life cycle at 10 AM.
Looking forward to hearing perspectives on efforts to improve the eco-impact of manufacturing especially because in 2025, US Pharmacopeia will launch a pillar of our 2025-2030 strategy to develop and revise USP public quality standards to reduce the environmental footprint of pharma manufacturing. We’ll be looking at natural resource usage in quality assurance, chemicals of concern, animal products used in quality assurance, and other ways to reduce environmental impact while maintaining quality.
To succeed, we will need the collaboration of regulators, and importantly, the pharma industry. We hope you will share the many advances in ‘greening’ the supply chain so that they can be incorporated into USP standards to broaden their usage in the US and around the world. This is all about impact for the planet and human health.
#DIA2024
#DIA2024 is the place to be! Thousands of attendees from across the globe are learning, engaging, and networking all with a shared goal: to solve the #healthcare challenges of today and improve access to life-changing treatments worldwide.
What sessions are you catching today?
Quality - Accreditation/Regulatory Specialist @Henry Ford Health | MBA
5moLooking forward to this event! Hope to see you there!! ❤️